To evaluate whether the tumor target ability of AIE@HFn and AIE@HFn-scfv were dependent on CD71 or Claudin18.2, we injected anti-CD71 IgG antibody as well as anti-Claudin18.2 IgG antibody via intraperitoneal injection 12 h before intravenous injection of AIE@HFn and AIE@HFn-scfv, respectively. Here, TFRC is linked to neoplasm.